Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia.

J Hematol Oncol · 2020 · PMC7487702 · PMID 32894185

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Childhood (age < 18 years old) experienced longer OS and RFS than did the adult patients ( p = 0.054 and 0.042, respectively), although these differences did not reach statistical significance on OS (Fig. 3 e, f).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.